Genmab (GMAB)
(Delayed Data from NSDQ)
$23.53 USD
-0.18 (-0.76%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $23.52 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.53 USD
-0.18 (-0.76%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $23.52 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Zacks News
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
INCY vs. GMAB: Which Stock Is the Better Value Option?
by Zacks Equity Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Should You Buy Genmab (GMAB) Ahead of Earnings?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
by Zacks Equity Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study
by Zacks Equity Research
Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
ALXN or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
by Zacks Equity Research
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
by Zacks Equity Research
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis
by Zacks Equity Research
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
by Zacks Equity Research
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
J&J (JNJ) Files BLA for Lung Cancer Candidate Amivantamab
by Zacks Equity Research
J&J (JNJ) files a BLA to the FDA for amivantamab for the treatment metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations.
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.